Mechanism of Action and Emerging Role of Immune Response Modifier Therapy in Dermatologic Conditions
- 1 December 2004
- journal article
- review article
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 8 (S3), 3-12
- https://doi.org/10.1007/s10227-004-0803-3
Abstract
Immune response modifiers (IRMs) are agents that target the body’s immune system (i.e., cytokines, receptors, and inflammatory cells) to combat disease. Topical IRM therapies, which encompass both proinflammatory and immunosuppressive therapeutics, have been used to successfully treat a number of dermatologic conditions. Proinflammatory treatments include Toll-like receptor agonists (e.g., imiquimod 5% cream) and interferon (e.g., interferon-α) therapies, which have been used in the treatment of external genital warts, basal cell carcinoma, and other dermatologic diseases. Immunosuppressive therapies include topical and intralesional corticosteroids, anti-tumor necrosis factor agents (e.g., infliximab and etanercept), and anti-CD4+ T-cell agents, including calcineurin inhibitors and mycophenolate. These agents have been used to treat a number of conditions, including atopic and seborrheic dermatitis and psoriasis. This article reviews the mechanism of action of IRMs and the application of IRMs in several dermatologic diseases.Keywords
This publication has 95 references indexed in Scilit:
- Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studiesJournal of the American Academy of Dermatology, 2004
- Tacrolimus effect on rosaceaJournal of the American Academy of Dermatology, 2004
- Safety of Tumour Necrosis Factor-?? AntagonistsDrug Safety, 2004
- Pros and Cons of Adjuvant Interferon in the Treatment of MelanomaThe Oncologist, 2003
- Efalizumab: an overviewJournal of the American Academy of Dermatology, 2003
- A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJournal of the American Academy of Dermatology, 2002
- Remission of Behcet's syndrome with TNFalpha blocking treatmentAnnals Of The Rheumatic Diseases, 2002
- Macrolactam immunomodulators for topical treatment of inflammatory skin diseasesJournal of the American Academy of Dermatology, 2001
- Intralesional interferon therapy for basal cell carcinomaJournal of the American Academy of Dermatology, 1990
- Therapy for cutaneous melanoma: An updateJournal of the American Academy of Dermatology, 1990